Mesoblast (MESO) vs Nuvation Bio (NUVB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Nuvation Bio (NUVB) has outperformed Mesoblast (MESO) over the past year, gaining 32.8% versus a loss of 22.9%. Over five years, MESO leads with a +22.7% price change compared with -49.1% for NUVB. Mesoblast is the larger company by market cap ($1.76 billion vs $1.64 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MESO | NUVB |
|---|---|---|
| Share price | $13.52 | $4.68 |
| Market cap | $1.76B | $1.64B |
| 1-day change | -3.01% | -3.81% |
| YTD return | -22.73% | -45.76% |
| 1-year return | -22.94% | +32.79% |
| 5-year return | +22.71% | -49.11% |
| Forward P/E | 29.71 | — |
| EPS (TTM) | $-0.44 | $-0.44 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $21.50 | $9.75 |
| 52-week low | $13.05 | $3.36 |
| Distance from 52-week high | -37.12% | -52.05% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +173.67% | +178.07% |
| Average volume | 232.53K | 5.65M |
| Shares outstanding | 129.85M | 350.12M |
| Employees | 108 | 305 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- NUVB has outperformed MESO by 55.7 percentage points over the past year.
About Mesoblast
MESO stock →Mesoblast Limited, together with its subsidiaries, engages in the development of regenerative medicine products in Australia. The company's proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 108 employees
About Nuvation Bio
NUVB stock →Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing product candidates for cancer treatment. The company's lead product candidate is IBTROZI (taletrectinib), a ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 305 employees
MESO vs NUVB FAQ
Which is bigger, Mesoblast or Nuvation Bio?
Mesoblast (MESO) is larger, with a market capitalization of $1.76B compared with $1.64B for Nuvation Bio (NUVB).
Which stock has performed better over the past year, MESO or NUVB?
NUVB returned +32.79% over the past 12 months, compared with -22.94% for MESO (price return, excluding dividends). Past performance does not predict future results.
Are Mesoblast and Nuvation Bio in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for Mesoblast and Biotechnology: Pharmaceutical Preparations for Nuvation Bio.